Uncover the promise of KRAS inhibitors in cancer treatment, as evidenced by a $200 million investment in BridgeBio's spinout.

Often called the Cellicon Valley due to its focus on cell and gene therapy, discover eight Philadelphia biotech companies to ...

We would like to learn more about you. Participate in the 2024 Labiotech Reader Survey for a chance to win a €250 or $250 ...

Coming under the area of regenerative medicine, orthobiologics is a rapidly advancing field that offers new options to treat acute orthopedic injuries and chronic or degenerative conditions without ...

On average, it takes 10.5 years for a drug to advance from phase 1 clinical trial to regulatory approval and market access. Between 2010 and 2020, the overall likelihood of approval was 7.9%. These ...

IgA nephropathy, a chronic kidney disease, is a condition that many scientists have been trying to cure over the years. While there still exists no cure, advancements in the field have been plenty in ...

The biotech industry job market is extremely competitive, making it difficult to identify where you can differentiate ...